Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lanreotide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR5 known ✓ | P35346 | 16/20 | 0.98 |
| ▸ | SSTR2 known ✓ | P30874 | 16/20 | 0.98 |
| ▸ | SSTR3 | P32745 | 8/20 | 0.98 |
| ▸ | SSTR1 | P30872 | 3/20 | 0.98 |
| ▸ | SSTR4 | P31391 | 8/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lanreotide SCHEMBL16767083 | 1.00 | SSTR5 (0.98) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| Lanreotide SCHEMBL29405684 | 1.00 | SSTR5 (0.98) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| Lanreotide SCHEMBL21050492 | 1.00 | SSTR5 (0.98) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| Lanreotide SCHEMBL16767086 | 1.00 | SSTR5 (0.98) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| Lanreotide SCHEMBL29846268 | 1.00 | SSTR5 (0.98) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| Lanreotide SCHEMBL22928940 | 0.99 | SSTR5 (1.00) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| Lanreotide SCHEMBL19472556 | 0.99 | SSTR5 (1.00) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| Lanreotide SCHEMBL21091289 | 0.99 | SSTR5 (1.00) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| Lanreotide SCHEMBL14674691 | 0.99 | SSTR5 (1.00) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| Lanreotide SCHEMBL19962799 | 0.99 | SSTR5 (1.00) | SSTR5SSTR2SSTR3SSTR1SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12466851-B2 | Manufacture of disulfide bonded peptides | BACHEM HOLDING AG (CH) | 2025-11-11 | — | — | US | disclosed |
| US-12031977-B2 | Ex vivo system for determining multiple drug-drug transporter interactions and methods of use thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2024-07-09 | — | — | US | disclosed |
| CN-110317188-B | Compound and preparation method and application thereof | 深圳翰宇药业股份有限公司 | 2023-01-17 | — | — | CN | disclosed |
| US-20220213139-A1 | MANUFACTURE OF DISULFIDE BONDED PEPTIDES | BACHEM HOLDING AG (CH) | 2022-07-07 | — | — | US | disclosed |
| EP-3956343-A1 | MANUFACTURE OF DISULFIDE BONDED PEPTIDES | Bachem Holding AG (CH) | 2022-02-23 | — | — | EP | disclosed |
| CN-114026107-A | Production of disulfide peptides | 巴克姆股份公司 | 2022-02-08 | — | — | CN | disclosed |
| US-20210231645-A1 | METHODS AND COMPOSITIONS FOR INVESTIGATING MULTIPLE DRUG-DRUG TRANSPORTER INTERACTIONS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2021-07-29 | — | — | US | disclosed |
| WO-2020212477-A1 | MANUFACTURE OF DISULFIDE BONDED PEPTIDES | BACHEM HOLDING AG (CH) | 2020-10-22 | — | — | WO | disclosed |
| CN-110317188-A | Compound and its preparation method and application | 深圳翰宇药业股份有限公司 | 2019-10-11 | — | — | CN | disclosed |
| WO-2019184089-A1 | COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 深圳翰宇药业股份有限公司 | 2019-10-03 | — | — | WO | disclosed |
| CN-108059667-B | A kind of solid phase synthesis process of Lanreotide | 润辉生物技术（威海）有限公司 | 2018-11-13 | — | — | CN | disclosed |
| CN-108059667-A | A kind of solid phase synthesis process of Lanreotide | 润辉生物技术（威海）有限公司 | 2018-05-22 | — | — | CN | disclosed |
| US-20160045463-A1 | USE OF METALLOPROTEASE INHIBITORS IN THE TREATMENT OF POLYCYSTIC LIVER DISEASES | UNIVERSIDAD DE SALAMANCA (ES) | 2016-02-18 | — | — | US | disclosed |
| EP-2926808-A1 | USE OF METALLOPROTEASE INHIBITORS FOR THE TREATMENT OF POLYCYSTIC LIVER DISEASES | Administración General De La Communidad Autónoma De Euskadi (ES) | 2015-10-07 | — | — | EP | disclosed |
| WO-2014083229-A1 | USE OF METALLOPROTEASE INHIBITORS FOR THE TREATMENT OF POLYCYSTIC LIVER DISEASES | ADMINISTRACIÓN GENERAL DE LA COMUNIDAD AUTÓNOMA DE EUSKADI (ES) | 2014-06-05 | — | — | WO | disclosed |
| WO-2013039916-A1 | COMPOSITIONS FOR AND METHODS OF TREATMENT AND ENHANCED DETECTION OF NON-PITUITARY TUMORS | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2013-03-21 | — | — | WO | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160045463-A1 | USE OF METALLOPROTEASE INHIBITORS IN THE TREATMENT OF POLYCYSTIC LIVER DISEASES | PKD1, MMP3, PKD2 | SSTR5 1131/4885SSTR2 1958/4885SSTR3 1706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.